ViaNautis Bio has begun collaborating with pharmaceutical company Eli Lilly to develop targeted genetic medicines.
Through the partnership, ViaNautis will receive an upfront payment from Lilly for the use of its polyNaut nanovesicles, with additional reimbursements for research, clinical and commercialisation milestones also being available to the biotech.
polyNaut nanovesicles are designed to deliver genetic materials in a highly specific manner — targeting only the tissue or cell type in question to treat a range of disease indications.
This technology could have the ability to improve the delivery of genetic medicines, potentially transforming treatment options for patients.
The collaboration has the potential to bolster Eli Lilly's targeted gene therapy portfolio, which aligns with the company's current plans to expand its CGT range to treat patients globally.
Co-founder of ViaNautis, Dr Francesca Crawford, commented: "This collaboration with Lilly is a testament to our polyNaut platform, which is also driving a highly differentiated emerging pipeline for severe life-limiting diseases."
"Combining our scientific know-how to precisely deliver genetic nanomedicines targeting difficult-to-reach sites, with Lilly's extensive drug development and commercialisation expertise will accelerate the creation of novel therapies to improve patient outcomes."
CEO of ViaNautis, Dr Adi Hoess, added: “I am very excited about our collaboration with Lilly to develop novel genetic medicines for patients in need."
"I want to thank Fran and the team for their hard work in getting to this key milestone and I look forward to working with Lilly to accelerate our shared vision of delivering targeted genetic medicines.”
